NASDAQ:GNCA - Genocea Biosciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.9650 0.00 (0.00 %)
(As of 06/19/2018 04:00 PM ET)
Previous Close$0.9650
Today's Range$0.93 - $1.00
52-Week Range$0.79 - $6.78
Volume428,808 shs
Average Volume949,318 shs
Market Capitalization$84.93 million
P/E Ratio-0.49
Dividend YieldN/A
Beta1.2
Genocea Biosciences logoGenocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Its lead immuno-oncology program is GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in preclinical stage, designed to direct a patient's immune system to attack tumor. The company is also seeking partners to develop cancer vaccines targeting tumor-associated antigens and a vaccine targeting cancers caused by Epstein-Barr virus. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Receive GNCA News and Ratings via Email

Sign-up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GNCA
CUSIPN/A
Phone617-876-8191

Debt

Debt-to-Equity Ratio1.00
Current Ratio8.06
Quick Ratio8.06

Price-To-Earnings

Trailing P/E Ratio-0.49
Forward P/E Ratio-1.61
P/E GrowthN/A

Sales & Book Value

Annual Sales$230,000.00
Price / Sales363.26
Cash FlowN/A
Price / CashN/A
Book Value($0.21) per share
Price / Book-4.60

Profitability

EPS (Most Recent Fiscal Year)($1.98)
Net Income$-56,710,000.00
Net MarginsN/A
Return on Equity-698.17%
Return on Assets-148.19%

Miscellaneous

Employees52
Outstanding Shares86,580,000

Genocea Biosciences (NASDAQ:GNCA) Frequently Asked Questions

What is Genocea Biosciences' stock symbol?

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

How were Genocea Biosciences' earnings last quarter?

Genocea Biosciences Inc (NASDAQ:GNCA) posted its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.14). View Genocea Biosciences' Earnings History.

When is Genocea Biosciences' next earnings date?

Genocea Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Genocea Biosciences.

What price target have analysts set for GNCA?

7 brokerages have issued 1-year price targets for Genocea Biosciences' stock. Their forecasts range from $2.50 to $10.00. On average, they expect Genocea Biosciences' stock price to reach $4.7857 in the next twelve months. View Analyst Ratings for Genocea Biosciences.

What are Wall Street analysts saying about Genocea Biosciences stock?

Here are some recent quotes from research analysts about Genocea Biosciences stock:
  • 1. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (4/18/2018)
  • 2. Cantor Fitzgerald analysts commented, "GNCA shares could experience some weakness on the news of the departure of the CFO, Jonathan Poole, who resigned effective 3/23, to pursue other opportunities." (3/11/2018)

Are investors shorting Genocea Biosciences?

Genocea Biosciences saw a decrease in short interest in the month of May. As of May 31st, there was short interest totalling 4,479,809 shares, a decrease of 22.9% from the May 15th total of 5,808,816 shares. Based on an average daily volume of 437,572 shares, the days-to-cover ratio is currently 10.2 days. Approximately 9.1% of the company's shares are short sold.

Who are some of Genocea Biosciences' key competitors?

Who are Genocea Biosciences' key executives?

Genocea Biosciences' management team includes the folowing people:
  • Mr. William D. Clark M.B.A., Pres, CEO & Director (Age 49)
  • Dr. George R. Siber M.D., Ph.D., Chairman of Scientific Advisory Board & Exec. Director (Age 73)
  • Dr. Darren Higgins Ph.D., Scientific Co-Founder and Member of Scientific Advisory Board
  • Dr. Jessica Baker Flechtner, Chief Scientific Officer (Age 46)
  • Mr. Eric S. Hoffman, Chief Bus. Officer (Age 48)

Has Genocea Biosciences been receiving favorable news coverage?

News articles about GNCA stock have trended somewhat positive this week, Accern reports. Accern identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Genocea Biosciences earned a daily sentiment score of 0.20 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 50.98 out of 100, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the immediate future.

Who are Genocea Biosciences' major shareholders?

Genocea Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include NEA Management Company LLC (30.45%), BVF Inc. IL (6.09%), BlackRock Inc. (4.82%), Northern Trust Corp (0.97%), GSA Capital Partners LLP (0.29%) and Birchview Capital LP (0.23%). Company insiders that own Genocea Biosciences stock include Eric S Hoffman, Jonathan Poole and William D Clark. View Institutional Ownership Trends for Genocea Biosciences.

Which institutional investors are buying Genocea Biosciences stock?

GNCA stock was bought by a variety of institutional investors in the last quarter, including NEA Management Company LLC, BVF Inc. IL, BlackRock Inc., Northern Trust Corp, GSA Capital Partners LLP, Schwab Charles Investment Management Inc., Birchview Capital LP and California State Teachers Retirement System. Company insiders that have bought Genocea Biosciences stock in the last two years include Eric S Hoffman, Jonathan Poole and William D Clark. View Insider Buying and Selling for Genocea Biosciences.

How do I buy shares of Genocea Biosciences?

Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genocea Biosciences' stock price today?

One share of GNCA stock can currently be purchased for approximately $0.9650.

How big of a company is Genocea Biosciences?

Genocea Biosciences has a market capitalization of $84.93 million and generates $230,000.00 in revenue each year. The biotechnology company earns $-56,710,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. Genocea Biosciences employs 52 workers across the globe.

How can I contact Genocea Biosciences?

Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at 617-876-8191 or via email at [email protected]


MarketBeat Community Rating for Genocea Biosciences (GNCA)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  231 (Vote Outperform)
Underperform Votes:  152 (Vote Underperform)
Total Votes:  383
MarketBeat's community ratings are surveys of what our community members think about Genocea Biosciences and other stocks. Vote "Outperform" if you believe GNCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.